Psoriatic arthritis (PsA), usually sero-negative for rheumatoid factor, is the second most common arthritis after rheumatoid arthritis (RA), accounting for 10-15% of patients presenting to early arthritis clinics (1, 2) . Psoriasis affects an estimated 2% of the general population, and arthritis complicates this in up to 10% of cases (3) . Until recently, compared with RA, PsA was considered to be a benign arthropathy, however the evidence suggests PsA may result in a destructive deforming arthropathy despite active treatment (4, 5) . Severe functional limitation may occur and a significant increase in the standardized mortality ratio in patients with PsA as compared to the general population is reported (4, 6) . The development of a uniform approach to the treatment of PsA has been hampered by many factors including the complex interaction of skin and joint disease, a reluctance to use disease modifying anti-rheumatic drugs (DMARD's) and importantly by a lack of evidence of the efficacy of these therapies from controlled studies. Currently initial therapy for PsA consists of non-steroidal anti-inflammatory drugs (NSAIDS) and local steroid injections, with DMARD`s being reserved for NSAID resistant or progressively destructive disease. Methotrexate (MTX), sulfasalazine and ciclosporin A (CSA) are the most widely used DMARD`s at present (7) , but many patients still fail to respond adequately. MTX is highly effective in the treatment of skin psoriasis (8) and there is evidence from small, open studies supporting a role in PsA (9) (10) (11) (12) (13) . Similarly, CSA is effective and widely used in the control of difficult psoriasis and there is evidence to support its use in PsA (14) (15) (16) (17) (18) (19) . The use of these agents as monotherapy in PsA is due in part to their potential benefits for both skin and joint disease, and they are familiar to both dermatologists and rheumatologists alike. Combination therapy with CSA and MTX has been demonstrated to result in a clinically important improvement with no substantial increase in side effects in RA (20) . There is uncontrolled evidence in a pilot study for additive efficacy without an increase in serious side effects in PsA (21) . This multi-center, double-blind, placebo controlled, randomized trial was designed to assess combination therapy of MTX plus CSA for the treatment of patients with active PsA.
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Chapter 4
Patients and Methods

Patients
Outpatients fulfilling the criteria for the diagnosis of PsA (1), were recruited from 5 clinical centers: Leeds, Amsterdam, Leuven, Maastricht and Brussels, after written informed consent was obtained. Local ethics committee approval for the study was obtained at each of the centers. Patients aged between 18 -70 years were included if they had a minimum disease duration of 24 weeks, evidence of skin and/or nail psoriasis and were seronegative for rheumatoid factor. Active PsA was defined as a minimum of 3 tender joints and patients must have had an incomplete response to a minimum of 15mgs of MTX weekly or lower if unable to tolerate a higher dose. Patients had to be taking MTX therapy for at least 3 months prior to screening and the MTX dose had to be stable for 1 month prior to screening and patients were permitted to be taking oral prednisolone (< 10mg per day) and/or NSAIDS provided the dose was stable for 1 month prior to baseline. Clinical subsets of PsA were not significantly different between groups and were defined as per Veale et al 1994 [1] : In both groups (MTX/CSA and MTX/Placebo), the symmetric polyarthritis subgroup was most frequent (53% and 61% respectively), followed by asymmetric oligoarthritis (44% and 39% respectively). One patient in the MTX/CSA group had asymmetric oligoarthritis and ankylosing spondylitis and no patients in the study had arthritis mutilans or isolated DIP joint disease. Patients were excluded from the study if they had abnormal hepatic or renal function, blood dyscrasia, or severe cardiac or respiratory disease.
Treatment groups and monitoring
Patients were randomly assigned to receive CSA or placebo in addition to MTX. The initial dose of CSA was 2.5mg/Kg/day and the dose was increased at weeks 4, 8 and 12 by 0.5mg/Kg/day, to a maximum dose of 4mg/Kg/day. CSA safety was determined by renal dysfunction and hypertension. If the serum creatinine increased during the treatment period by 30% then the CSA dosage was reduced in accordance to a predetermined titration table. An increase in the mean diastolic blood pressure to between 95-110 mmHg at 2 consecutive visits triggered the introduction of an appropriate anti-hypertensive agent and if this did not result in a decrease below 95 mmHg by the next visit, then the study medication was reduced. The dose of MTX was reduced by 50% if an increase in AST (SGOT) or ALT (SGPT), of two times the upper limit of normal occurred. CSA and MTX were discontinued and the patient withdrawn if two consecutive dose reductions failed to normalize the clinical parameter triggering the dosage titration.
Assessments
Clinical assessments (22) , including joint assessments based on a 68 joint model, were undertaken at baseline (week 0) and weeks 2, 4, 8, 12, 16, 20, 24, 30, 36, 42 and 48. Tender joint articular index was evaluated at all visits except weeks 16 and 36. If a joint was injected less than 3 months prior to screening then this was recorded and noted at each subsequent assessment, and if a joint required injection during the study, the joint was assessed prior to injection and the injection was noted and recorded at subsequent assessments. The secondary efficacy parameters were a) tender joint count b) swollen joint count c) ESR and/or CRP (all visits) d) change in the psoriasis area and severity index (PASI) (23) evaluated at weeks 4, 12, 24, 36 and 48 e) change in patients assessment of pain (100 mm VAS) at each visit f) change in patients global assessment of disease activity (100 mm VAS) at each visit g) change in physicians global assessment of disease activity (100mm VAS) at each visit h) the change in quality of life as assessed by the health assessment questionnaire (HAQ) at weeks 24 and 48 (24) i) the change in Larsen and Dale damage score between baseline and weeks 24 and 48 as assessed by x-ray j) high resolution ultrasound (HRUS) assessment of synovitis (at the Leeds site only) X-rays of the hands and feet were assessed by two musculoskeletal radiologists aware of the chronological order of the films but blinded to patient identity. Joint scoring was carried out in accordance with the Larsen-Dale method (25) . In addition patients at one centre had high resolution ultrasonography (HRUS) performed at baseline and study completion as part of the study protocol. An ATL HDI 3000 machine was used. The 2nd to 5th metacarpophalangeal (MCP) and proximalinterphalangeal (PIP) joints of the dominant hand were scanned by one blinded rheumatologist experienced in US. Assessment for synovitis was undertaken as previously described and validated in PsA (26, 27) 
Statistical analysis
The primary measure of efficacy was the change from baseline to final visit (12 months) in joint tenderness as measured by the modified Ritchie index. Taking into account published experience (18, 28, 29) response rates of 25 % in the treatment arm and 5% in the placebo arm were employed as the basis of a sample size calculation. A sample size of 112 was calculated to have 80% power to detect a difference between the treatment groups with 5% significance and a 20% dropout rate. The efficacy analysis was carried out on the intention to treat (ITT) population which is defined as all patients who received trial medication, provided baseline efficacy data and from whom at least one post-baseline measurement was obtained. The endpoint measurement for each randomized patient was the last post-randomization measurement carried forward. The safety population were all patients receiving at least on dose of study medication. The Mann-Whitney U test was used to assess the statistical significance of differences between groups. P values of less than 0.05 were considered significant.
Results
Seventy two consecutive patients underwent screening and 72 were randomized. The baseline characteristics of the patients are summarized in Table 1 and no significant differences were noted between groups. There were no significant differences between the two groups at baseline. The mean disease duration for PsA was only 3-4 years and of the 72 patients enrolled, 21 of 38 (55.3%) in the MTX/CSA group and 23 of 34 (67.6%) in the MTX/placebo group, completed the 12 month regimen of study medication. 
Clinical results
Significant improvements were noted in both the MTX/CSA and MTX/placebo groups between baseline and study end but significant differences between the groups were noted in PASI score and Ultrasound detected synovitis. However in the MTX/CyA group, significant clinical improvements from baseline were also detected in some parameters which were not evident in the MTX/placebo group. These study outcomes are summarized in Table 2 .
The tender joint index (TJI) improved from 35. All parameters are shown as mean ± standard deviation (SD). Significant differences from baseline are indicated (* = p <0.05, ** = p < 0.001) and significant between group differences ( † = P < 0.05). TJI, tender joint index; TJC, tender joint count; SJC, swollen joint count; ESR erythrocyte sedimentation rate; CRP, C-reactive protein; PASI, psoriasis area and severity index; VAS, visual analogue scale; HAQ, health assessment questionnaire.
CSA group, mean ± SD, 32.9 ± 26 to 34.6 ± 24; and MTX/placebo group, 36 ± 28 to 43.4 ± 33, (NS). These study outcomes are shown in Figure 1 .
High resolution ultrasound
High resolution ultrasound assessment of joints for synovitis showed a significant reduction in mean adjusted number of definite or probable synovitic joints detected per person in the MTX/CSA group (-2.5, 95% CI -4.07 to -1.01) as compared to the MTX/placebo group (-0.282, 95% CI -1.67 to 1.1) (p<0.05). The overall number of joints with synovitis in the placebo group was 64 out of 95 (67.3%) at baseline and 58 out of 95 (61%) at 48 weeks. In the MTX/CSA group 42 out of 77 (58%) joints assessed showed synovitis at baseline and 20 out of 77 (25%) at week 48 (p < 0.05), as shown in Figure 2 . Adverse events recorded more frequently in the MTX/CSA than placebo group are shown in Table 3 . There was 1 (2.9%) serious adverse event in the MTX/placebo group and 4 (10.5%) in the MTX/CSA group, including 1 new diagnosis of ovarian carcinoma and 1 new diagnosis of interstitial lung disease. Seventeen patients in the MTX/CSA group and 11 in the MTX/placebo group were withdrawn from the study treatment before 6 months. The reasons for withdrawal are shown in Table 4 . The number of patients withdrawn from the study due to an adverse event were 13 (34.2%) in the MTX/CSA group and 2 (5.9%) in the MTX/placebo group. Studies of CSA at high dose in organ transplantation have demonstrated frequent side effects such as hypertrichosis and gingivitis which can interfere with clinical blinding. At doses used in arthritis and psoriasis however, these side effects do not appear as frequent, despite careful surveillance, as confirmed by this and previous studies (8, 20) . 
Study drug dosage and adverse events
Discussion
Improvements in arthritis were detected in the MTX/CSA treated group and not in the placebo group with respect to swollen joint count and CRP and HRUS-detected synovitis was significantly reduced compared to placebo. This suggests that in PsA patients having only a partial response to MTX therapy the addition of CSA may offer clinically important benefits.
A more aggressive approach to treatment of PsA has not only resulted in the earlier use of DMARD`s and at higher doses, but also, following the RA model, the proposed use of combination therapy. Tugwell et al studied the use of combination MTX and CSA in RA and reported this combination to be statistically more effective than monotherapy with MTX without any significant increase in toxicity (20) . The combination of MTX and CSA in the treatment of PsA would appear intuitive as a step up for the resistant/ severe patient. Both agents are used for severe skin and joint disease, but with different and potentially complimentary modes of action which may result in therapeutic synergy. Specifically, MTX has important effects in PsA at the level of the synovium including reducing synovial membrane infiltration with T cells and macrophages and the expression of pro-inflammatory cytokines (30) . It is also now clear that cytokines are raised in PsA joint fluid and tissue and have a significant pathogenic role (31) . Psoriasis and PsA are believed to be largely T-cell mediated diseases demonstrating greater levels of neovascularisation than is seen in RA (32), and CyA is known to be a specific T-cell inhibitor, with potent anti-angiogenic properties (33, 34) . Two previous uncontrolled studies have suggested additive efficacy without an increase in serious side effects when MTX and CSA are used together in PsA (21, 35) . Surprisingly, marked improvements in clinical outcomes were found in both the placebo group and the active treatment group. Improvements in the placebo controlled groups of previous PsA studies, above that seen in RA studies, have been reported before (36) . This may reflect a cyclical pattern of symptomatology experienced by PsA patients who may be recruited to studies during a symptom flare and consequently note some degree of spontaneous improvement. Despite this, improvements in SJC and CRP from baseline were noted in the MTX/CSA group and HRUS detected synovitis reduced significantly in the MTX/CSA group as compared to placebo. It is not surprising from a pathophysiological viewpoint that these 3 parameters appear to improve in a correlated fashion as SJC is a clinical measure of joint synovitis, serum CRP levels will reflect total synovial inflammation, and HRUS is an objective and sensitive tool for detecting and quantifying synovitis. Consequently the most convincing evidence for efficacy relates to the HRUS as opposed to purely clinical parameters. Greater synovial activity might be expected to result in greater bony change, but despite a deterioration in the Larsen score in the MTX/placebo group of over 20% versus 5% in MTX/CSA, this difference wasn't significant. It would appear therefore that adding CSA to MTX in active PsA has resulted in a significant reduction in inflammation not seen in the placebo controlled group. A significant improvement in the PASI score of patients in the MTX/CSA group compared to the MTX/placebo group was noted, demonstrating a beneficial additive efficacy in psoriasis confirming the additive benefit of these agents in the treatment of skin psoriasis at least. Despite this, no significant improvements were demonstrated in either patient global assessments of pain or disease activity or indeed quality of life. It may be argued that this supports a disassociation between the presence of synovitis and symptoms in PsA.
Undoubtedly the high level of spontaneous improvement in the MTX/placebo group and a degree of underecruitment resulted in this study being underpowered, despite some clinical benefits from combining CSA with MTX being demonstrated. The risk of Type II error has to be considered to be significant and conclusions, outside of the positive benefits demonstrated, should be guarded for the reasons outlined above. Fewer patients in the MTX/CSA group completed the study than in the MTX/placebo group and there were more drug related adverse events in the MTX/CSA group than the MTX/placebo group. These figures reflect previously published data which point towards some increase in toxicity resulting in higher dropout rates for CSA than MTX (28) . It would appear that etanercept is currently the only therapeutic agent with sufficient data from placebo controlled, randomized studies to receive a Food and Drug Administration indication for the treatment of PsA in the United States of America (37) . Despite this, few people currently recommend the use of anti-TNFα as first line in the treatment of PsA and consequently we need to develop our evidence base for the implementation of escalating therapy in difficult/aggressive PsA prior to the use of biological agents. In this study we demonstrate clinical benefits in terms of reduced levels of inflammation at 12 months in patients with active PsA. It would appear that combination therapy with CSA and MTX in patients with active PsA and persistent inflammation despite adequate monotherapy with DMARD's, is a valid therapeutic option for the reduction of synovitis.
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